Netflix's Q3 Earnings Report Could Lead to $21.5 Billion Swing in Market Value

Earnings are in focus on Thursday, with a -selected slate that runs from industrial engines and logistics real estate to streaming and medical devices. With guidance and segment commentary often moving stocks as much as the headline numbers, the options market offers a real-time snapshot of how much volatility traders are bracing for, according to Pro. The marquee name on this list is UnitedHealth Group Inc. (NYSE: UNH ), but the biggest implied move is saved for the final section as the countdown runs from the calmest setup to the most volatile.

6. 83% Prologis, Inc. (NYSE: PLD ) reports second quarter of 2026 results before the opening bell. 04 billion a year ago.

08 billion of market value at stake. 3 billion square feet of industrial and logistics facilities globally, putting rent growth, occupancy and any demand read-through at the center of the print. The stock carries a Buy consensus rating, and the stock is trading below the 180-day average analyst price forecast; in July, BTIG reiterated its Buy rating and raised its price forecast, while in June Scotiabank downgraded the stock to Sector Perform and cut its price forecast. 9% above the 200-day moving average.

41. Read Also: Mohamed El-Erian Predicts Gas Prices Will Hit $4 a Gallon by the End of the Month as GOP Blames Democrats' Clean Energy Strategy 5. 85% GE Aerospace (NYSE: GE ) reports second quarter of 2026 results before the opening bell. 02 billion in the prior-year quarter.

2 billion of market value at stake given GE Aerospace’s $376 billion market cap. GE Aerospace designs, manufactures and services commercial aircraft turbine engines, including through its CFM joint venture with Safran — a setup that keeps investors keyed in on engine deliveries, aftermarket demand and any margin commentary. The stock carries a Buy consensus rating, and the share price sits below the 180-day average analyst price forecast; in July, TD Cowen, Susquehanna and Jefferies raised their price forecasts. 6% above the 200-day moving average.

75. 4. 35% Abbott Laboratories (NYSE: ABT ) reports second quarter of 2026 results before the opening bell. 14 billion a year earlier.

35% move. 25 billion of market value at stake. Abbott Laboratories sells a broad mix spanning cardiovascular and diabetes devices, nutrition products, diagnostics, and branded generics — meaning investors often focus on which segments are driving growth rather than the consolidated top line alone. The stock carries a Buy consensus rating, and the 180-day average analyst price forecast sits well above where the stock trades; in July, Evercore ISI Group reiterated its Outperform rating and cut its price forecast, and Baird initiated coverage with an Outperform rating.

8% below the 200-day moving average. 49. 3. UnitedHealth Group Inc.

44% UnitedHealth Group Inc. reports second quarter of 2026 results before the opening bell. 62 billion in the year-ago quarter. 6 billion of market value at stake given UnitedHealth Group’s $378 billion market cap.

UnitedHealth Group is one of the largest private health insurers, providing medical benefits to about 51 million members globally as of December 2025. The stock carries a Buy consensus rating, and shares trade below the 180-day average analyst price forecast; in July, TD Cowen, Truist Securities and Keybanc raised their price forecasts. 5% above the 200-day moving average. 60.

2. Netflix Inc. 91% Netflix Inc. (NASDAQ: NFLX ) reports second quarter of 2026 results after the closing bell.

08 billion a year ago. 5 billion of market value at stake for the $311 billion streaming giant. Netflix runs a single core business — its streaming service — with more than 300 million subscribers globally, keeping the market’s attention on subscriber trends, engagement and the revenue trajectory implied by the quarter’s outlook. The stock carries a Buy consensus rating, and the stock is trading well below the 180-day average analyst price forecast; in July, Morgan Stanley reiterated its Overweight rating and cut its price forecast, while Barclays reiterated its Equal-Weight rating and cut its price forecast